Development of a Gram-negative selective agar (GNSA) for the detection of Gram-negative microflora in sputa in patients with cystic fibrosis

Journal of Applied Microbiology

Volumn 95, Issue 1, 2003, Pages 160-166

  Moore, John E ^a   Xu, J ^a   Millar, B C ^a   Courtney, J ^b   Elborn, J S ^b  

^a BELFAST CITY HOSPITAL   (United Kingdom)

^b QUEEN'S UNIVERSITY BELFAST   (United Kingdom)

Author keywords

Burkholderia cepacia; Culture; Cystic fibrosis; Pseudomonas aeruginosa; Qualitative; Quantitative; Selective; Stenotrophomonas maltophila

Indexed keywords

ALGAE; ANTIBIOTICS; BACTERIA; PATIENT TREATMENT; POLYSACCHARIDES;

AGAR MEDIA; BURKHOLDERIA CEPACIA; CULTURE; CYSTIC FIBROSIS; PSEUDOMONAS AERUGINOSA; QUALITATIVE; QUANTITATIVE; SELECTIVE; STENOTROPHOMONA MALTOPHILUM; STENOTROPHOMONAS;

YEAST;

AGAR; AMPHOTERICIN; CRYSTAL VIOLET; CYCLOHEXIMIDE; NISIN; NOVOBIOCIN;

MICROBIOLOGY;

ACHROMOBACTER XYLOSOXIDANS; ADULT; ARTICLE; AUTOMATION; BACTERIAL FLORA; BACTERIAL GROWTH; BACTERIUM DETECTION; BRONCHUS SECRETION; BURKHOLDERIA CEPACIA; CULTURE MEDIUM; CYSTIC FIBROSIS; FEMALE; FUNGUS; GRAM NEGATIVE BACTERIUM; HUMAN; MALE; NONHUMAN; PSEUDOMONAS AERUGINOSA; SPUTUM ANALYSIS; STENOTROPHOMONAS MALTOPHILIA; YEAST;

ACHROMOBACTER XYLOSOXIDANS; ALCALIGENES; BACTERIA (MICROORGANISMS); BRONCHUS; BURKHOLDERIA; BURKHOLDERIA CENOCEPACIA; BURKHOLDERIA CEPACIA; FUNGI; NEGIBACTERIA; POSIBACTERIA; PSEUDOMONAS; PSEUDOMONAS AERUGINOSA; STENOTROPHOMONAS; STENOTROPHOMONAS MALTOPHILIA; VIOLA (ANGIOSPERM);

EID: 0038386749     PISSN: 13645072     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2672.2003.01956.x     Document Type: Article

References (18)

1. Bauernfeind, A., Bertele, R.M., Harms, K., Horl, G., Jungwirth, R., Petermuller, C., Przyklenk, B. and Weisslein-Pfister, C. (1987) Qualitative and quantitative microbiological analysis of sputa of 102 patients with cystic fibrosis. Infection 15, 270-277.
2. Brockow, K., Grabenhorst, P., Abeck, D., Traupe, B., Ring, J., Hoppe, U. and Wolf, F. (1999) Effect of gentian violet, corticosteroid and tar preparations in Staphylococcus-aureus-colonized atopic eczema. Dermatology 199, 231-236.
3. Burns, J.L., Emerson, J., Stapp, J.R., Yim, D.L., Krzewinski, J., Louden, L., Ramsey, B.W. and Clausen, C.R. (1998) Microbiology of sputum from patients at cystic fibrosis centers in the United States. Clinical Infectious Diseases 27, 158-163.
4. Burns, J.L, Van Dalfsen, J.M., Shawar, R.M., Otto, K.L., Garber, R.L., Quan, J.M., Montgomery, A.B., Albers, G.M., Ramsey, B.E. and Smith, A.L. (1999) Effect of chronic intermittent administration of inhaled tobramycin on respiratory microbial flora in patients with cystic fibrosis. Journal of Infectious Diseases 179, 1190-1196.
5. Gaylor, A.S. and Reilly, J.C. (2002) Therapy with macrolides in patients with cystic fibrosis. Pharmacotherapy 22, 227-239.
6. Goto, S. and Enomoto, S. (1970) Nalidixic acid cetrimide agar. A new selective plating medium for the selective isolation of Pseudomonas aeruginosa. Japanese Journal of Microbiology 14, 65-72.
7. Hamdy, A.H., Olds, N.L. and Roberts, B.J. (1975) Activity of penicillin and novobiocin against bovine mastitis pathogens. American Journal of Veterinary Research 36, 259-262.
8. Henry, D.A., Campbell, M.E., LiPuma, J.J. and Speert, D.P. (1997) Identification of Barkholderia cepacia isolates from patients with cystic fibrosis and use of a simple new selective medium. Journal of Clinical Microbiology 35, 614-619.
9. Maduri-Traczewski, M., L'Heureux, C., Escalona, L., Macone, A. and Goldmann, D. (1986) Facilitated detection of antibiotic-resistant Pseudomonas in cystic fibrosis sputum using homogenized specimens and antibiotic-containing media. Diagnostic Microbiology and Infectious Diseases 5, 299-305.
10. Michaud, D. (2001) Liposomal amphotericin B for the treatment of severe fungal infection dynamics 12, 17-21.
11. Millar, B., Moore, J., Mallon, P., Xu, J., Crowe, M., McClurg, R., Raoult, D., Earle, J., Hone, R. and Murphy, P. (2001) Molecular diagnosis of infective endocarditis - a new Duke's criterion. Scandinavian Journal of Infectious Diseases 33, 673-680.
12. Moore, J.E., Millar, B.C., Buckley, T., Crowe, M. and Elborn, J.S. (2002a) Effect of high-temperature short-time (HTST) laboratory pasteurization on the survival of Burkholderia cepacia complex organisms in whole, low fat and skimmed milks. Journal of Dairy Research 69, 483-490.
13. Moore, J.E., Xu, J., Millar, B.C., Crowe, M. and Elborn, J.S. (2002b) Improved molecular detection of Burkholderia cepacia genomovar III and Burkholderia multivorans directly from sputum of patients with cystic fibrosis. Journal of Microbiological Methods 49, 183-191.
14. Rajah, S. and Saiman, L. (2002) Pulmonary infections in patients with cystic fibrosis. Seminars in Respiratory Infection 17, 47-56.
15. Ramsey, B.W., Pepe, M.S., Quan, J.M., Otto, K.L., Montgomery, A.B., Williams-Warren, J., Vasiljev, K.M., Borowitz, D., Bowman, C.M., Marshall, B.M., Marshall, S. and Smith, A.L. (1999) Intermittent administration of inhaled tobramycin in patients with cystic fibrosis. Cystic Fibrosis Inhaled Tobramycin Study Group. New England Journal of Medicine 340, 23-30.
16. Severina, E., Severin, A. and Tomasz, A. (1998) Antibacterial efficacy of nisin against multidrug-resistant Gram-positive pathogens. Journal of Antimicrobial Chemotherapy 41, 341-347.
17. Wolter, J., Seeney, S., Bell, S., Bowler, S., Masel, P. and McCormack, J. (2002) Effect of long term treatment with azithromycin on disease parameters in cystic fibrosis: a randomised trial. Thorax 57, 212-216.
18. Wong, K., Roberts, M.C., Owens, L., Fife, M. and Smith, A.L. (1984) Selective media for the quantitation of bacteria in cystic fibrosis sputum. Journal of Medical Microbiology 17, 113-119.